Clinical Trials Browser

Phase 2 × Sezary Syndrome × RFT5-SMPT-dgA immunotoxin × Clear all

NCT00667017 2018-12-14

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

1 enrolled 1 chart

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous